The development of resistance to traditional antifungal therapies has necessitated the exploration of alternative treatment strategies to effectively manage fungal infections, particularly those induced by Candida albicans (C. albicans). This research investigates the possibility of integrating silver nanoparticles (AgNPs) with Terbinafine to improve antifungal effectiveness. Terbinafine, while potent, faces challenges with specific fungal strains, highlighting the need for strategies to enhance its treatment efficacy. Silver nanoparticles were produced through a light-activated, gelatin-based method, resulting in particle sizes ranging from 56.8 nm to 66.2 nm, confirmed by dynamic light scattering and scanning electron microscopy. Stability studies indicated that AgNPs produced with 30 mg of silver nitrate (AgNO₃) exhibited the greatest stability over 60 days across different temperature conditions. The analysis through UV-visible spectrophotometry revealed a notable shift in the absorption spectra as AgNO₃ concentrations increased, which was associated with a strengthening of plasmon resonance. The effectiveness of the AgNPs and Terbinafine combination was assessed against three strains of C. albicans (ATCC 10231, ATCC 90028, and ATCC 18804). Terbinafine demonstrated strong antifungal properties with minimum inhibitory concentrations (MIC) values ranging from 2–4 µg/mL, whereas AgNPs on their own displayed moderate effectiveness. The integrated formulation notably enhanced effectiveness, especially against strain ATCC 90028, revealing a synergistic effect (FIFi = 0.369). These results were complemented by the findings of the time-to-kill assay, where the same strain showed a 3.2 log₁₀ CFU/mL decrease in viable cell count. The process by which AgNPs boost activity entails the disruption of the fungal cell membrane and its internal components, probably as a result of silver ion release and the generation of free radicals. The results indicate that the combination of Terbinafine and AgNPs may act as a powerful alternative for addressing resistant fungal infections, presenting an encouraging direction for future antifungal treatments.
Background: Leishmaniasis remains a neglected tropical disease with high global disease burden and limited safe therapeutic options. Medicinal plants offer an important source of bioactive compounds for drug development. Objective: This study aimed to isolate and characterize bioactive compounds from Asparagus gracilis and evaluate their antileishmanial potential using both in vitro and in silico approaches. Methods: The plant was shade-dried, extracted with methanol, and fractionated using solvents of increasing polarity. Bioactive fractions were subjected to column chromatography, and compounds were characterized by proton nuclear magnetic resonance (^1H-NMR). Antileishmanial activity was assessed against Leishmania tropica promastigotes using the MTT assay. Molecular docking was performed against leishmanolysin GP63 (PDB: 1LML) using MOE software. Results: The ethyl acetate fraction displayed the highest antileishmanial activity with an IC₅₀ value of 13.5 µg/mL. Ferulic acid was isolated at 4% ethyl acetate–n-hexane solvent system and identified as the major bioactive compound. The compound exhibited dose-dependent inhibition of L. tropica promastigotes with an IC₅₀ of 11.1 µg/mL. Docking studies revealed strong binding affinity with GP63, showing four hydrogen bonds and a binding energy of −5.9 kcal/mol. Conclusion: The results suggest that ferulic acid from A. gracilis exhibits promising antileishmanial activity. This compound can serve as a potential lead for the development of new antileishmanial agents.